Response to questions regarding the design and results of the IMPACT trial

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 177-178

  Humar, Atul ^a  

^a IMPACT Investigators Steering Committee ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALGANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; GANCICLOVIR; KIDNEY TRANSPLANTATION; RANDOM ALLOCATION; RESEARCH DESIGN;

EID: 78650907480     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03370.x     Document Type: Letter

References (5)

1. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valgancivloir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
2. Humar A, Limaye AP, Blumberg EA, et al,. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: IMPACT study 2-year results. Transplant 2010; Dec Suppl ()
3. Paya C, Humar Atul, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
4. Palmer SM, Limaye AP, Banks M, et al,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. Ann Intern Med 2010; 152: 761-769.
5. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A,. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449-2458.